ro-16-0154 has been researched along with 1-(3-chlorophenyl)piperazine* in 1 studies
1 trial(s) available for ro-16-0154 and 1-(3-chlorophenyl)piperazine
Article | Year |
---|---|
gamma-Aminobutyric acid-serotonin interactions in healthy men: implications for network models of psychosis and dissociation.
This study tested the hypothesis that deficits in gamma-aminobutyric acid type A (GABA(A)) receptor function might create a vulnerability to the psychotogenic and perceptual altering effects of serotonergic (5-HT(2A/2C)) receptor stimulation. The interactive effects of iomazenil, an antagonist and partial inverse agonist of the benzodiazepine site of the GABA(A) receptor complex, and m-chlorophenylpiperazine (m-CPP), a partial agonist of 5-HT(2A/2C) receptors, were studied in 23 healthy male subjects.. Subjects underwent 4 days of testing, during which they received intravenous infusions of iomazenil/placebo followed by m-CPP/placebo in a double-blind, randomized crossover design. Behavioral, cognitive, and hormonal data were collected before drug infusions and periodically for 200 min after.. Iomazenil and m-CPP interacted in a synergistic manner to produce mild psychotic symptoms and perceptual disturbances without impairing cognition. Iomazenil and m-CPP increased anxiety in an additive fashion. Iomazenil and m-CPP interacted in a synergistic manner to increase serum cortisol.. Gamma-aminobutyric acid-ergic deficits might increase the vulnerability to the psychotomimetic and perceptual altering effects of serotonergic agents. These data suggest that interactions between GABA(A) and 5-HT systems might contribute to the pathophysiology of psychosis and dissociative-like perceptual states. Topics: Analysis of Variance; Anxiety; Cross-Over Studies; Dissociative Disorders; Double-Blind Method; Drug Synergism; Flumazenil; GABA Modulators; gamma-Aminobutyric Acid; Humans; Male; Models, Neurological; Perceptual Disorders; Piperazines; Psychoses, Substance-Induced; Receptors, GABA-A; Receptors, Serotonin, 5-HT2; Reference Values; Serotonin; Serotonin Receptor Agonists | 2006 |